001     862746
005     20220930130211.0
024 7 _ |a 10.1038/s41598-019-41993-6
|2 doi
024 7 _ |a 2128/22182
|2 Handle
024 7 _ |a pmid:30952881
|2 pmid
024 7 _ |a WOS:000463482800054
|2 WOS
024 7 _ |a altmetric:58931090
|2 altmetric
037 _ _ |a FZJ-2019-02988
082 _ _ |a 600
100 1 _ |a Elfgen, Anne
|0 P:(DE-Juel1)164354
|b 0
|u fzj
245 _ _ |a Metabolic resistance of the D-peptide RD2 developed for direct elimination of amyloid-β oligomers
260 _ _ |a [London]
|c 2019
|b Macmillan Publishers Limited, part of Springer Nature
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1583736742_29854
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Alzheimer’s disease (AD) is a neurodegenerative disorder leading to dementia. Aggregation of the amyloid-β peptide (Aβ) plays an important role in the disease, with Aβ oligomers representing the most toxic species. Previously, we have developed the Aβ oligomer eliminating therapeutic compound RD2 consisting solely of D-enantiomeric amino acid residues. RD2 has been described to have an oral bioavailability of more than 75% and to improve cognition in transgenic Alzheimer’s disease mouse models after oral administration. In the present study, we further examined the stability of RD2 in simulated gastrointestinal fluids, blood plasma and liver microsomes. In addition, we have examined whether RD2 is a substrate for the human D-amino acid oxidase (hDAAO). Furthermore, metabolite profiles of RD2 incubated in human, rodent and non-rodent liver microsomes were compared across species to search for human-specific metabolites that might possibly constitute a threat when applying the compound in humans. RD2 was remarkably resistant against metabolization in all investigated media and not converted by hDAAO. Moreover, RD2 did not influence the activity of any of the tested enzymes. In conclusion, the high stability and the absence of relevant human-specific metabolites support RD2 to be safe for oral administration in humans.
536 _ _ |a 553 - Physical Basis of Diseases (POF3-553)
|0 G:(DE-HGF)POF3-553
|c POF3-553
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef
700 1 _ |a Hupert, Michelle
|0 P:(DE-Juel1)142389
|b 1
|u fzj
700 1 _ |a Bochinsky, Kevin
|0 P:(DE-Juel1)165763
|b 2
|u fzj
700 1 _ |a Tusche, Markus
|0 P:(DE-Juel1)131709
|b 3
700 1 _ |a González de San Román Martin, Estibaliz
|0 P:(DE-Juel1)168323
|b 4
700 1 _ |a Gering, Ian
|0 P:(DE-Juel1)171922
|b 5
|u fzj
700 1 _ |a Sacchi, Silvia
|0 0000-0002-2338-2561
|b 6
700 1 _ |a Pollegioni, Loredano
|0 0000-0003-1733-7243
|b 7
700 1 _ |a Huesgen, Pitter F.
|0 P:(DE-Juel1)162356
|b 8
700 1 _ |a Hartmann, Rudolf
|0 P:(DE-Juel1)132001
|b 9
700 1 _ |a Santiago-Schübel, Beatrix
|0 P:(DE-Juel1)133853
|b 10
|u fzj
700 1 _ |a Kutzsche, Janine
|0 P:(DE-Juel1)159137
|b 11
|e Corresponding author
|u fzj
700 1 _ |a Willbold, Dieter
|0 P:(DE-Juel1)132029
|b 12
|e Corresponding author
773 _ _ |a 10.1038/s41598-019-41993-6
|g Vol. 9, no. 1, p. 5715
|0 PERI:(DE-600)2615211-3
|n 1
|p 5715
|t Scientific reports
|v 9
|y 2019
|x 2045-2322
856 4 _ |u https://juser.fz-juelich.de/record/862746/files/16003723690008973348INVOIC2676139755001.pdf
856 4 _ |u https://juser.fz-juelich.de/record/862746/files/16003723690008973348INVOIC2676139755001.pdf?subformat=pdfa
|x pdfa
856 4 _ |u https://juser.fz-juelich.de/record/862746/files/Metabolic%20resistance%20of%20the%20D-peptide%20RD2%20developed%20for%20direct%20elimination%20of%20amyloid-%CE%B2%20oligomers.pdf
|y OpenAccess
856 4 _ |u https://juser.fz-juelich.de/record/862746/files/Metabolic%20resistance%20of%20the%20D-peptide%20RD2%20developed%20for%20direct%20elimination%20of%20amyloid-%CE%B2%20oligomers.pdf?subformat=pdfa
|x pdfa
|y OpenAccess
909 C O |o oai:juser.fz-juelich.de:862746
|p openaire
|p open_access
|p OpenAPC
|p driver
|p VDB
|p openCost
|p dnbdelivery
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 0
|6 P:(DE-Juel1)164354
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 1
|6 P:(DE-Juel1)142389
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 2
|6 P:(DE-Juel1)165763
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 3
|6 P:(DE-Juel1)131709
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 5
|6 P:(DE-Juel1)171922
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 8
|6 P:(DE-Juel1)162356
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 9
|6 P:(DE-Juel1)132001
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 10
|6 P:(DE-Juel1)133853
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 11
|6 P:(DE-Juel1)159137
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 12
|6 P:(DE-Juel1)132029
913 1 _ |a DE-HGF
|b Key Technologies
|l BioSoft – Fundamentals for future Technologies in the fields of Soft Matter and Life Sciences
|1 G:(DE-HGF)POF3-550
|0 G:(DE-HGF)POF3-553
|2 G:(DE-HGF)POF3-500
|v Physical Basis of Diseases
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
914 1 _ |y 2019
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1040
|2 StatID
|b Zoological Record
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b SCI REP-UK : 2017
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1150
|2 StatID
|b Current Contents - Physical, Chemical and Earth Sciences
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
920 _ _ |l yes
920 1 _ |0 I:(DE-Juel1)ICS-6-20110106
|k ICS-6
|l Strukturbiochemie
|x 0
920 1 _ |0 I:(DE-Juel1)ZEA-3-20090406
|k ZEA-3
|l Analytik
|x 1
980 1 _ |a APC
980 1 _ |a FullTexts
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-Juel1)ICS-6-20110106
980 _ _ |a I:(DE-Juel1)ZEA-3-20090406
980 _ _ |a APC
980 _ _ |a UNRESTRICTED
981 _ _ |a I:(DE-Juel1)IBI-7-20200312


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21